Market Snapshot
| Study Period: | 2018 - 2026 |
| Base Year: | 2021 |
| Fastest Growing Market: | Asia Pacific |
| Largest Market: | North America |
| CAGR: | 7.6 % |
|
Need a report that reflects how COVID-19 has impacted this market and its growth?
Market Overview
The sepsis therapeutics market is projected to register a CAGR of 7.6% over the forecast period. The major factor attributing to the growth of the market is the rising incidence of sepsis globally. According to the World Health Organization, it is estimated to affect more than 30 million people worldwide every year, potentially leading to 6 million deaths. The burden of sepsis is most likely the highest in the low- and middle-income countries. Furthermore, increasing research and development programs and funding are the factors boosting the market's growth.
However, the lack of initial diagnostic test for identifying sepsis conditions and the lack of awareness about the treatment are the factors constraining the market's growth.
Scope of the Report
As per the scope of the report, sepsis occurs when the body’s response to an infection injures its own tissues and organs, potentially leading to death or significant morbidity This report is segmented by drug class, route of administration, and geography.
| By Drug Class | |
| Aminoglycosides | |
| Cephalosporin | |
| Glycopeptide Antibiotics | |
| Other Drug Classes |
| By Route of Administration | |
| Intravenous | |
| Oral |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Key Market Trends
Cephalosporins Dominate the Sepsis Therapeutics Market
The dominant share of the segment is attributed to the vast usage of the drug class, individually or in combination with the other drugs.
Cephalosporins are divided into the first, second, third, and fourth generation. First-generation cephalosporins have greater activity against gram-positive bacteria. The succeeding generations have increased activity against gram-negative bacteria and decreased activity against gram-positive bacteria.
Apart from the advantages and broad-spectrum activity of cephalosporins, the increasing incidence of sepsis is expected to boost the segment's growth.
To understand key trends, Download Sample Report
North America Dominates the Market and Expected to do Same in the Forecast PeriodNorth America is expected to dominate the overall sepsis therapeutics market, throughout the forecast period. The largest share is mainly due to presence of larger patient pool and increasing geriatric population. Furthermore, well-established insurance policies and the availability of advanced healthcare infrastructure are few of the other factors boosting the market in this region. In North America region, the United States holds the largest market share due to the factors such as increasing number of geriatric populations, along with a growing number of patient pool in the country. According to Sepsis.org., more than 1.7 million people in the country are diagnosed with sepsis each year, one every 20 seconds and the incidence is rising 8% every year and the cost of hospitalization in the U.S. consuming more than USD 27 billion each year. As per the statistics the large patient pool and high disposable income propels the market growth in the region.
North America is expected to dominate the overall sepsis therapeutics market, throughout the forecast period. The largest share is mainly due to the presence of larger patient pool and increasing geriatric population. Furthermore, well-established insurance policies and the availability of advanced healthcare infrastructure are few of the other factors boosting the market in this region. In North America region, the United States holds the largest market share due to the factors such as increasing number of geriatric populations, along with a growing number of patient pool in the country. According to Sepsis.org., more than 1.7 million people in the country are diagnosed with sepsis each year, one every 20 seconds and the incidence is rising 8% every year and the cost of hospitalization in the U.S. consuming more than USD 27 billion each year. As per the statistics the large patient pool and high disposable income propels the market growth in the region.
To understand geography trends, Download Sample Report
Competitive Landscape
The sepsis therapeutics market is moderately competitive. A few of the crucial approaches followed by players are product development, invention, acquisitions, and mergers. Some of the companies currently dominating the market are F. Hoffmann-La Roche Ltd, Pfizer Inc., GlaxoSmithKline Inc., Mylan NV, and Allergan Inc.
Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Increasing Incidence of Sepsis
-
4.2.2 Increasing Geraiatric Poulation
-
4.2.3 Rise in the Number of Pipeline Products and Upsurge in Research and Development Expenditures
-
-
4.3 Market Restraints
-
4.3.1 Lack of Initial Diagnostic Test for identifying Sepsis Conditions and Lack of Awareness
-
-
4.4 Porter's Five Force Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Drug Class
-
5.1.1 Aminoglycosides
-
5.1.2 Cephalosporin
-
5.1.3 Glycopeptide Antibiotics
-
5.1.4 Other Drug Classes
-
-
5.2 By Route of Administration
-
5.2.1 Intravenous
-
5.2.2 Oral
-
-
5.3 Geography
-
5.3.1 North America
-
5.3.1.1 United States
-
5.3.1.2 Canada
-
5.3.1.3 Mexico
-
-
5.3.2 Europe
-
5.3.2.1 Germany
-
5.3.2.2 United Kingdom
-
5.3.2.3 France
-
5.3.2.4 Italy
-
5.3.2.5 Spain
-
5.3.2.6 Rest of Europe
-
-
5.3.3 Asia-Pacific
-
5.3.3.1 China
-
5.3.3.2 Japan
-
5.3.3.3 India
-
5.3.3.4 Australia
-
5.3.3.5 South Korea
-
5.3.3.6 Rest of Asia-Pacific
-
-
5.3.4 Middle-East and Africa
-
5.3.4.1 GCC
-
5.3.4.2 South Africa
-
5.3.4.3 Rest of Middle-East and Africa
-
-
5.3.5 South America
-
5.3.5.1 Brazil
-
5.3.5.2 Argentina
-
5.3.5.3 Rest of South America
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 F. Hoffmann-La Roche Ltd
-
6.1.2 Pfizer Inc.
-
6.1.3 GlaxoSmithKline Inc.
-
6.1.4 Mylan NV
-
6.1.5 Allergan Inc.
-
6.1.6 Asahi Kasei Corporation
-
6.1.7 RegeneRx
-
6.1.8 Inotrem SA
-
6.1.9 Endacea Inc.
-
6.1.10 Adrenomed AG
-
*List Not Exhaustive -
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Sepsis Therapeutics Market market is studied from 2018 - 2026.
What is the growth rate of Sepsis Therapeutics Market?
The Sepsis Therapeutics Market is growing at a CAGR of 7.6% over the next 5 years.
Which region has highest growth rate in Sepsis Therapeutics Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Sepsis Therapeutics Market?
North America holds highest share in 2020.
Who are the key players in Sepsis Therapeutics Market?
F. Hoffmann-La Roche Ltd, Pfizer Inc., GlaxoSmithKline Inc, Mylan N.V. , Allergan, Inc. are the major companies operating in Sepsis Therapeutics Market.
